We are conducting a multicenter, randomized, open-label trial to evaluate the safety and efficacy of SGLT2i in resolving DME with a combination of anti-VEGF agents and SGLT2i in patients with type 2 diabetes and DME [31]. The gene discussed is VEGFA; the disease is type 2 diabetes mellitus.